Harriet Kluger
Yale University · Professor of Medicine · Yale New Haven Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Harriet Kluger as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:17 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07027488 · AB821 in Adult Participants With Locally Advanced or Metastatic Solid TumorsYale University · recruiting · Advanced Melanoma and Normal or Impaired, Advanced Melanoma · principal investigator
- Ph2NCT06521762 · Etrasimod for Immune Checkpoint Inhibitor Diarrhea and ColitisYale University · withdrawn · Immune Checkpoint Inhibitor-Related Diarrhea and Colitis · principal investigator
- Ph2NCT04955743 · Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaYale University · terminated · Melanoma, Renal Cell Carcinoma, Brain Metastases · principal investigator
- Ph1NCT04495257 · A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)Yale University · completed · Advanced Melanoma, Renal Cell Carcinoma · principal investigator
- Ph1NCT03502330 · APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaYale University · completed · Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma · principal investigator
- Ph2NCT02230306 · Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain MetastasesMelissa Burgess, MD · terminated · Active Melanoma Brain Metastases · principal investigator
- Ph2NCT02085070 · MK-3475 in Melanoma and NSCLC Patients With Brain MetastasesYale University · completed · Melanoma, Non-Small Cell Lung Cancer, Brain Metastases · principal investigator
- Ph1/Ph2NCT01350401 · Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic MelanomaAdaptimmune · terminated · Melanoma · principal investigator
- Ph2NCT00436605 · Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV MelanomaNational Cancer Institute (NCI) · completed · Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Career Enhancement ProgramP50CA196530 · NCI · YALE UNIVERSITY · fiscal years 2020 to 2026 · $134,308 awarded in 2026Same name and institution; not confirmed by an ID
- Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapyR01CA269349 · NCI · YALE UNIVERSITY · fiscal years 2023 to 2026 · $674,193 awarded in 2026Same name and institution; not confirmed by an ID
- Immune Therapy for Brain MetastasisR01CA269286 · NCI · YALE UNIVERSITY · fiscal years 2023 to 2026 · $550,079 awarded in 2026Same name and institution; not confirmed by an ID
- Project 3. Overcoming Melanoma Treatment Resistance with Cytokine ImmunotherapyP50CA121974 · NCI · YALE UNIVERSITY · fiscal years 2012 to 2026 · $435,395 awarded in 2026Grant number is on one of their registry trials
- YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAMK12CA215110 · NCI · YALE UNIVERSITY · fiscal years 2018 to 2026 · $717,601 awarded in 2026Same name and institution; not confirmed by an ID
- Cancer Research Training and Education CoordinationP30CA016359 · NCI · YALE UNIVERSITY · fiscal years 2018 to 2024 · $138,487 awarded in 2024Grant number is on one of their registry trials
- (8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitorsR01CA227473 · NCI · YALE UNIVERSITY · fiscal years 2018 to 2022 · $554,845 awarded in 2022Same name and institution; not confirmed by an ID
- Renalase inhibition for treatment of unresectable melanomaR01CA216846 · NCI · YALE UNIVERSITY · fiscal years 2017 to 2021 · $481,477 awarded in 2021Same name and institution; not confirmed by an ID
- A research and training program for junior clinicians in treating metastatic melaK24CA172123 · NCI · YALE UNIVERSITY · fiscal years 2013 to 2017 · $156,084 awarded in 2017Same name and institution; not confirmed by an ID
- Models to Predict Prognosis and Benefit from Adjuvant Therapy in Renal Cell CarciR01CA158167 · NCI · YALE UNIVERSITY · fiscal years 2011 to 2015 · $355,126 awarded in 2015Same name and institution; not confirmed by an ID
- Predicting Melanoma Response to BAY 43-9006/ChemotherapyR01CA115756 · NCI · YALE UNIVERSITY · fiscal years 2005 to 2008 · $268,903 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:17 UTC. The ranking covers the 200 most relevant of 39 PubMed records, and a shared surname and initials can bring in a namesake. All 39 on PubMed
- Nivolumab plus ipilimumab in advanced melanoma.N Engl J Med · 20133,396 citationsRCR 92.1
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J Clin Oncol · 20141,889 citationsRCR 53.5
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.N Engl J Med · 20161,007 citationsRCR 30.3
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.Lancet Oncol · 2016841 citationsRCR 26.0
- Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.Lancet Oncol · 2020467 citationsRCR 18.2
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.J Clin Oncol · 2015370 citationsRCR 10.2
- 332 citationsRCR 20.2
- Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.Sci Transl Med · 2014315 citationsRCR 8.3
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.J Clin Oncol · 2019310 citationsRCR 10.5
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.Clin Cancer Res · 2016246 citationsRCR 6.6